Skip to main content
. 2024 Jan 4;30(2):543–551. doi: 10.1038/s41591-023-02703-y

Extended Data Table 3.

A. Ocular AEs in the 3.4 mg/kg SPLIT Dose Cohort; B. Belamaf Dosing in the 3.4 mg/kg SPLIT Dose Cohort; C. Pomalidomide Dosing in the 3.4 mg/kg SPLIT Dose Cohort

graphic file with name 41591_2023_2703_Tab3_ESM.jpg

AE, adverse event; BCVA, best corrected visual acuity; No., number.